Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
11 Feb 2019
Historique:
received: 17 12 2018
accepted: 04 02 2019
entrez: 13 2 2019
pubmed: 13 2 2019
medline: 14 6 2019
Statut: epublish

Résumé

The diagnosis of depression, a frequent comorbidity of chronic obstructive pulmonary disease (COPD), is often supported by questionnaires, such as the Patient Health Questionnaire 9 (PHQ-9). It is unknown to which extent its single questions are affected by the clinical characteristics of COPD patients.We addressed this question in 2255 GOLD grade 1-4 patients from the COSYCONET (COPD and Systemic Consequences - Comorbidities Network) COPD cohort. The dependence on COPD severity was assessed using symptoms, exacerbation risk (GOLD A-D; modified Medical Research Council dyspnoea scale (mMRC)), and frequent comorbidities as predictors of PHQ-9 results, while including age, gender, body mass index (BMI) and smoking habits as covariates.Symptoms and exacerbation risk were associated with depression in an additive manner, with mean elevations in the PHQ-9 sum score by 2.75 and 1.44 points, respectively. Asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases by 0.8 to 1.3 points. Overall, the COPD characteristics contributed to the mean PHQ-9 score by increases from 4.5 or 5.2 to 6.3 points, respectively, when either taking GOLD A as reference or the absence of comorbidities. This finding was independent of the diagnosis of mental disorder or the intake of antidepressants. The presence of COPD led to an increase in the proportion of scores indicating depression from 12 to 22%. Single item analysis revealed homogenous effects regarding GOLD groups, but heterogeneous effects regarding GOLD grades.These findings indicate specific effects of COPD severity on the PHQ-9 depression score, especially symptoms and exacerbation risk, explaining the high prevalence of depression in COPD. Alternative explanations like an overlap of COPD severity and PHQ-9 items are discussed. Of note, we also found COPD treatment effects on depression scores.

Identifiants

pubmed: 30744630
doi: 10.1186/s12931-019-0997-y
pii: 10.1186/s12931-019-0997-y
pmc: PMC6371561
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30

Subventions

Organisme : German Federal Ministry of Education and Research
ID : 01 GI 0881
Organisme : AstraZeneca GmbH
ID : not applicable
Organisme : Bayer Schering Pharma AG
ID : not applicable
Organisme : Boehringer Ingelheim Pharma GmbH & Co. KG
ID : not applicable
Organisme : Chiesi GmbH
ID : not applicable
Organisme : GlaxoSmithKline
ID : not applicable
Organisme : Grifols Deutschland GmbH
ID : not applicable
Organisme : MSD Sharp & Dohme GmbH
ID : not applicable
Organisme : Mundipharma GmbH
ID : not applicable
Organisme : Novartis Deutschland GmbH
ID : not applicable
Organisme : Pfizer Pharma GmbH
ID : not applicable
Organisme : Takeda Pharma Vertrieb GmbH & Co
ID : not applicable

Références

JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Psychosomatics. 2006 Jan-Feb;47(1):62-7
pubmed: 16384809
Fam Pract. 2007 Jun;24(3):217-23
pubmed: 17504776
BMJ. 2009 Mar 19;338:b750
pubmed: 19299475
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Psychiatry (Edgmont). 2009 Jan;6(1):38-51
pubmed: 19724742
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Gen Hosp Psychiatry. 2011 May-Jun;33(3):217-23
pubmed: 21601717
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Chest. 2013 Sep;144(3):766-777
pubmed: 23429910
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):733-9
pubmed: 23703492
Dtsch Arztebl Int. 2013 Jun;110(23-24):413-9
pubmed: 23837086
J Korean Med Sci. 2013 Jul;28(7):1048-54
pubmed: 23853488
Eur Respir J. 2014 Sep;44(3):734-43
pubmed: 24876171
Addict Behav. 2014 Oct;39(10):1418-29
pubmed: 24935795
Eur Respir Rev. 2014 Sep;23(133):345-9
pubmed: 25176970
J Affect Disord. 2015 Jan 1;170:138-42
pubmed: 25240840
Int J Chron Obstruct Pulmon Dis. 2014 Dec 04;10:1321-9
pubmed: 25587219
Curr Opin Pulm Med. 2016 Mar;22(2):125-9
pubmed: 26814143
Respir Med. 2016 May;114:27-37
pubmed: 27109808
BMC Pulm Med. 2016 May 10;16(1):70
pubmed: 27160582
Respir Res. 2016 Jul 12;17(1):81
pubmed: 27405652
Respir Med. 2016 Aug;117:154-61
pubmed: 27492526
J Am Geriatr Soc. 2016 Nov;64(11):e201-e206
pubmed: 27783384
PLoS One. 2016 Oct 28;11(10):e0163408
pubmed: 27792735
Respirology. 2017 Apr;22(3):575-601
pubmed: 28150362
J Clin Diagn Res. 2017 Feb;11(2):OC24-OC27
pubmed: 28384911
Medicine (Baltimore). 2017 May;96(19):e6836
pubmed: 28489768
Psychiatry Investig. 2017 May;14(3):306-313
pubmed: 28539949
J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24
pubmed: 29169740
Respir Med. 2018 Jan;134:79-85
pubmed: 29413512
Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605
pubmed: 30282573

Auteurs

Sarah Marietta von Siemens (SM)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.

Rudolf A Jörres (RA)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.

Jürgen Behr (J)

Department of Internal Medicine V, University of Munich (LMU), Ziemssenstr. 1, 80336, Munich, Germany.

Peter Alter (P)

Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL), Baldingerstrasse, 35043, Marburg, Germany.

Johanna Lutter (J)

Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstädter Landstr. 1, 85764, Munich, Germany.

Tanja Lucke (T)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.

Sandra Söhler (S)

ASCONET Study Coordination Office, University of Marburg, Baldingerstraße, 35043, Marburg, Germany.

Tobias Welte (T)

Department of Pneumology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Henrik Watz (H)

Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Woehrendamm 80, 22927, Grosshansdorf, Germany.

Claus F Vogelmeier (CF)

Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL), Baldingerstrasse, 35043, Marburg, Germany.

Franziska Trudzinski (F)

Department of Internal Medicine V - Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Straße 1, 66424, Homburg, Germany.

Winfried Rief (W)

Department of Clinical Psychology and Psychotherapy, Philipps-University Marburg, Germany, Gutenbergstraße 18, 35032, Marburg, Germany.

Britta Herbig (B)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.

Kathrin Kahnert (K)

Department of Internal Medicine V, University of Munich (LMU), Ziemssenstr. 1, 80336, Munich, Germany. Kathrin.Kahnert@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH